Apnimed (APMD) files for Nasdaq IPO with oral sleep apnea drug
As seen on the 24/7 Wall St. homepage on July 10, 2026.
Sleep apnea biotech Apnimed files to go public on Nasdaq, banking on its oral drug candidate to displace CPAP machines as the market's standard treatment.
Continue ReadingShow less
Apnimed, Inc. has registered for an operating IPO on the Nasdaq under the proposed ticker APMD, marking its first formal step toward trading as a public company. The biotech is built around an oral drug candidate it hopes can challenge the dominant position of CPAP machines in the sleep apnea treatment market.
CPAP therapy, while effective, is notoriously difficult for patients to tolerate long-term, and the industry has long searched for a simpler alternative. Apnimed is betting that a pill-based approach could win over both patients and physicians who struggle with CPAP compliance, potentially opening a large and underserved addressable market.
Disclosure
*$149 for two years (or $1.43 per week) is an introductory promotion for new members only. 62% discount based on the current list price of Stock Advisor of $199/year. Membership will renew at the then-current list price at the end of the membership term. Stock Advisor returns are 930% as compared to the S&P 500 returns of 185% as of April 7, 2026.
The same investor newsletter that told subscribers to buy Amazon in 2002, Netflix in 2004, and Nvidia in 2005 still publishes two new stock picks every month. Over 23 years, Motley Fool's Stock Advisor has more than quadrupled the S&P 500. New members get this month's picks, the Top 10 Rankings, and a 30-day money-back guarantee. Click here to unlock their next top stocks while new members are still being accepted.
The filing is in the registered stage, meaning key details such as share price range, shares offered, and total deal size have not yet been disclosed. Investors watching the IPO will want to monitor subsequent SEC amendments for those figures as the offering moves closer to pricing.
Mentioned: APMD